Opaleye Management’s Viridian Therapeutics VRDN Stock Holding History

Opaleye Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-25,667	Closed	-$1.17M	–	60
2018 Q4	$1.17M	Sell	25,667 -67,380	-72%	-$3.9M	0.44%	39
2018 Q3	$7.79M	Buy	93,047 +13,047	+16%	+$1.23M	1.98%	18
2018 Q2	$7.69M	Buy	+80,000	New	+$8.46M	1.99%	15

Other funds holding VRDN

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Opaleye Management's VRDN Position: Q1 2019 in Review

Opaleye Management sold out of Viridian Therapeutics (VRDN) in Q1 2019, closing a stake of 25,667 shares — an estimated $1.17M sold.

Opaleye Management first reported a position in VRDN in Q2 2018 and held it in 3 quarters. The position peaked at $7.79M in Q3 2018. 51 funds tracked by Wall St. Rank hold VRDN as of Q1 2019.

Opaleye Management reported no remaining Viridian Therapeutics position as of Q1 2019 after selling out during the quarter.
Opaleye Management sold 25,667 Viridian Therapeutics shares in Q1 2019, an estimated $1.17M.
Opaleye Management first reported a position in Viridian Therapeutics in Q2 2018 and held it in 3 quarters.
Opaleye Management's Viridian Therapeutics position peaked at $7.79M in Q3 2018.
51 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2019.

Based on Opaleye Management's 13F filing for Q1 2019, filed 15 May 2019.